Document Detail


Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
MedLine Citation:
PMID:  19561526     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic diseases. Although effective under optimal conditions, several drawbacks are imminent to the long-term application of these drugs due to their narrow therapeutic window, interactions with other drugs as well as the need for regular monitoring and the risk of a recurrent event versus the risk of bleeding. To overcome these downsides, novel anticoagulants are being developed; in contrast to vitamin K antagonists, these novel agents specifically and selectively block central elements of the coagulation cascade. Several clinical trials have demonstrated the efficacy and safety of selective FXa inhibitors (such as fondaparinux, rivaroxaban, apixaban) and direct thrombin inhibitors (such as lepirudin, bivalirudin, dabigatran etexilate) in the treatment of typical indications for conventional vitamin K antagonists, in particular, the prevention and treatment of venous thromboembolism. This review summarizes the results and designs of recently published and ongoing clinical trials of novel anticoagulants.
Authors:
Jan Steffel; Thomas F Lüscher
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  10     ISSN:  1558-2027     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-08     Completed Date:  2009-09-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  616-23     Citation Subset:  IM    
Affiliation:
CardioVascular Center, University Hospital Zurich, Switzerland bInstitute of Physiology, Cardiovascular Research, University of Zurich-Irchel, Zurich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / pharmacology,  therapeutic use*
Factor Xa / antagonists & inhibitors*
Humans
Stroke / prevention & control
Thrombin / antagonists & inhibitors*
Thromboembolism / prevention & control*
Chemical
Reg. No./Substance:
0/Anticoagulants; EC 3.4.21.5/Thrombin; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does Stress Reduction Change the Levels of Cortisol Secretion in Patients With Coronary Artery Disea...
Next Document:  5-Fluorouracil-induced coronary vasospasm.